文献速递冠心病心力衰竭与心肌病

基于适配体的大规模蛋白质组学分析在计划性心肌梗死中的应用

Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions.
PubMed 文献 · Circulation · 2017-12-08

本研究应用可检测4783种人类蛋白的适配体蛋白质组学平台,在计划性心肌损伤(室间隔酒精消融)推导队列(n=20)和验证队列(n=15)中寻找早期心肌损伤标志物,并与自发性心肌梗死患者(n=63)及高危对照比较。结果表明大规模适配体多重检测可行,为心肌损伤后生物标志物和通路发现提供了新机会。

要点

  • 适配体平台可同时检测4783种蛋白,样本通量远超现有蛋白质组学方法。
  • 29个早期升高蛋白在自发性心梗患者中也升高,部分为新型细胞内蛋白。

核心结论

  • 大规模适配体多重检测技术可行,样本通量超越现有蛋白质组学方法。
  • 该平台为心肌损伤后生物标志物和通路发现提供了独特机会。

研究设计与样本

  • 应用单链DNA适配体平台检测4783种人类蛋白(4137个基因靶点)。
  • 纳入计划性心肌损伤推导队列(n=20)和验证队列(n=15)。
  • 纳入自发性心肌梗死患者(n=63)和高危对照。
  • 采用重复测量方差分析和Bonferroni校正进行统计比较。

主要发现

  • 计划性心肌损伤后376个蛋白显著变化(推导队列n=20;P<1.05E-05)。
  • 29个计划性心肌损伤后1小时内升高的蛋白在自发性心梗患者中也升高(n=63;P<6.17E-04)。
  • 许多新标志物为既往外周循环未发现的细胞内蛋白或具有心肌损伤相关功能。

关键数值与推荐

  • 推导队列显著变化阈值:P<1.05E-05(单因素重复测量方差分析,Bonferroni阈值)。
  • 验证队列显著变化阈值:P<1.33E-04(单因素重复测量方差分析)。
  • 自发性心梗中升高阈值:P<6.17E-04。

临床怎么用

  • 该平台可用于心肌损伤早期生物标志物的发现和验证。
  • 发现的蛋白标志物有望辅助心肌损伤的早期识别和机制研究。

局限性

  • 计划性心肌损伤模型样本量较小(推导n=20,验证n=15)。
  • 研究结果需在更广泛人群和临床场景中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging proteomic technologies using novel affinity-based reagents allow for efficient multiplexing with high-sample throughput. To identify early biomarkers of myocardial injury, we recently applied an aptamer-based proteomic profiling platform that measures 1129 proteins to samples from patients undergoing septal alcohol ablation for hypertrophic cardiomyopathy, a human model of planned myocardial injury. Here, we examined the scalability of this approach using a markedly expanded platform to study a far broader range of human proteins in the context of myocardial injury. METHODS: We applied a highly multiplexed, expanded proteomic technique that uses single-stranded DNA aptamers to assay 4783 human proteins (4137 distinct human gene targets) to derivation and validation cohorts of planned myocardial injury, individuals with spontaneous myocardial infarction, and at-risk controls. RESULTS: We found 376 target proteins that significantly changed in the blood after planned myocardial injury in a derivation cohort (n=20; P<1.05E-05, 1-way repeated measures analysis of variance, Bonferroni threshold). Two hundred forty-seven of these proteins were validated in an independent planned myocardial injury cohort (n=15; P<1.33E-04, 1-way repeated measures analysis of variance); >90% were directionally consistent and reached nominal significance in the validation cohort. Among the validated proteins that were increased within 1 hour after planned myocardial injury, 29 were also elevated in patients with spontaneous myocardial infarction (n=63; P<6.17E-04). Many of the novel markers identified in our study are intracellular proteins not previously identified in the peripheral circulation or have functional roles relevant to myocardial injury. For example, the cardiac LIM protein, cysteine- and glycine-rich protein 3, is thought to mediate cardiac mechanotransduction and stress responses, whereas the mitochondrial ATP synthase F0 subunit component is a vasoactive peptide on its release from cells. Last, we performed aptamer-affinity enrichment coupled with mass spectrometry to technically verify aptamer specificity for a subset of the new biomarkers. CONCLUSIONS: Our results demonstrate the feasibility of large-scale aptamer multiplexing at a level that has not previously been reported and with sample throughput that greatly exceeds other existing proteomic methods. The expanded aptamer-based proteomic platform provides a unique opportunity for biomarker and pathway discovery after myocardial injury.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Jacob J, Ngo D, Finkel N, et al. Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial Infarctions. Circulation. 2017. PMID: 29222138. doi:10.1161/CIRCULATIONAHA.117.029443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。